We are live on
!
Find out more
ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
1-Year Est. Return
7.38%
This Fund
S&P 500
This Quarter
Est. Return
-2.69%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$195M
AUM Growth
-$51.6M
(-21%)
Cap. Flow
-$43.8M
Cap. Flow
% of AUM
-22.52%
Top 10 Holdings %
Top 10 Hldgs %
61.32%
Holding
72
New
17
Increased
14
Reduced
19
Closed
22
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$17.8M |
| 2 |
Becton Dickinson
BDX
|
+$17.1M |
| 3 |
Sabra Healthcare REIT
SBRA
|
+$9.02M |
| 4 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$7.54M |
| 5 |
Qiagen
QGEN
|
+$6.63M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Labcorp
LH
|
+$10.9M |
| 2 |
Centene
CNC
|
+$9.85M |
| 3 |
Merck
MRK
|
+$8.25M |
| 4 |
Icon
ICLR
|
+$7.14M |
| 5 |
Cigna
CI
|
+$6.37M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.97% |
| 2 | Real Estate | 8.02% |
| 3 | Miscellaneous | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
BioMarin Pharmaceuticals
BMRN
$12.5B
| $24.9M | 12.77% |
255,616
+171,259
| +203% | +$17.8M |
|
|
2
Becton Dickinson
BDX
$49.5B
| $19M | 9.77% |
76,850
+70,089
| +1,037% | +$17.1M |
|
3
Elevance Health
ELV
$89.5B
| $17.2M | 8.82% |
37,326
+11,249
| +43% | +$5.35M |
|
|
4
Sabra Healthcare REIT
SBRA
$5.13B
| $13.4M | 6.89% |
1,165,923
+729,399
| +167% | +$9.02M |
|
|
5
Labcorp
LH
$26.3B
| $10.4M | 5.33% |
52,659
-53,177
| -50% | -$10.9M |
|
|
6
Qiagen
QGEN
$8.86B
| $8.22M | 4.22% |
168,707
+130,278
| +339% | +$6.63M |
|
|
7
Cigna
CI
$74.1B
| $7.1M | 3.65% |
27,799
-21,879
| -44% | -$6.37M |
|
8
AstraZeneca
AZN
$253B
| $6.75M | 3.47% |
48,629
-22,081
| -31% | -$2.97M |
|
|
9
Teva Pharmaceutical Industries Limited
TEVA
$44.9B
| $6.75M | 3.47% |
+762,264
| New | +$7.54M |
|
|
10
Icon
ICLR
$13.4B
| $5.73M | 2.94% |
26,830
-32,066
| -54% | -$7.14M |
|
11
Moderna
MRNA
$58.1B
| $5.55M | 2.85% |
+36,130
| New | +$5.96M |
|
|
12
Merck
MRK
$358B
| $5.27M | 2.71% |
49,573
-76,430
| -61% | -$8.25M |
|
13
Avantor
AVTR
$10.6B
| $4.77M | 2.45% |
+225,615
| New | +$5.14M |
|
14
Bio-Rad Laboratories Class A
BIO
$10.1B
| $4.4M | 2.26% |
9,185
+5,292
| +136% | +$2.48M |
|
15
Insmed
INSM
$26.8B
| $3.92M | 2.01% |
230,006
-13,116
| -5% | -$255K |
|
16
Tenet Healthcare
THC
$21.4B
| $3.56M | 1.83% |
59,903
+19,451
| +48% | +$1.08M |
|
17
Cartesian Therapeutics
RNAC
$239M
| $3.01M | 1.55% |
72,211
-53,710
| -43% | -$2.52M |
|
18
Pfizer
PFE
$157B
| $2.99M | 1.54% |
+73,265
| New | +$3.16M |
|
19
Ocular Therapeutix
OCUL
$2.17B
| $2.7M | 1.39% |
512,744
-551,209
| -52% | -$2.62M |
|
20
McKesson
MCK
$103B
| $2.6M | 1.34% |
+7,312
| New | +$2.64M |
|
21
PTC Therapeutics
PTCT
$5.64B
| $2.58M | 1.32% |
53,247
+35,361
| +198% | +$1.62M |
|
22
DexCom
DXCM
$33B
| $2.58M | 1.32% |
+22,185
| New | +$2.48M |
|
23
argenx
ARGX
$61.6B
| $2.29M | 1.17% |
+6,137
| New | +$2.27M |
|
24
Healthpeak Properties
DOC
$14B
| $2.21M | 1.14% |
100,685
+41,107
| +69% | +$1.02M |
|
25
Dentsply Sirona
XRAY
$2.02B
| $2.2M | 1.13% |
55,992
+33,904
| +153% | +$1.24M |
|
Similar funds
UVM
VAFP
CA
SCM
FWM
TOPU
CCMU
TGI
Endurant Capital Management's Q1 2023 Portfolio in Review
As of Q1 2023, Endurant Capital Management held 72 positions worth $195M, down 21% from $246M the previous quarter. Its ten largest holdings account for 61% of the portfolio.
Endurant Capital Management withdrew a net $43.8M in Q1 2023, closing 22 positions and reducing 19 holdings. Its most notable exit was Elutia, an estimated $5.35M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 74% a quarter earlier, followed by Real Estate and Miscellaneous.
Against the trend, Endurant Capital Management opened a new position in Teva Pharmaceutical Industries Limited worth $6.75M.
- Endurant Capital Management's largest Q1 2023 buy was Teva Pharmaceutical Industries Limited: 762,264 shares worth $6.75M.
- Endurant Capital Management added most to BioMarin Pharmaceuticals in Q1 2023, an estimated $17.8M increase.
- Endurant Capital Management's biggest Q1 2023 reduction was Labcorp, cutting an estimated $10.9M.
- Endurant Capital Management fully exited Elutia in Q1 2023, selling an estimated $5.35M.
- Endurant Capital Management's ten largest holdings make up 61% of its $195M portfolio in Q1 2023.
- Endurant Capital Management opened 17 new positions and closed 22 in Q1 2023.
- Endurant Capital Management's portfolio value fell 21% quarter-over-quarter to $195M.
Based on Endurant Capital Management's 13F filing for Q1 2023, filed 15 May 2023.